Craft

Corvus Pharmaceuticals

Stock Price

$2.1

2024-05-13

Market Capitalization

$132 M

2024-05-13

Corvus Pharmaceuticals Summary

Company Summary

Overview
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. The Company is developing new drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. One of these agents is an oral immune checkpoint inhibitor that has been through human safety testing where it demonstrated favorable safety and pharmacologic properties. It recently entered cancer clinical trials.
Type
Public
Status
Active
Founded
2014
HQ
Burlingame, CA, US | view all locations
Website
http://corvuspharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Richard A. Miller

    Richard A. Miller, Co-Founder, President and CEO, Chairman

    • Ian T. Clark

      Ian T. Clark, Director

      • Leiv Lea

        Leiv Lea, CFO

        • James W. Janc

          James W. Janc, Vice President, Pharmacology

          Operating MetricsView all

          Patent Applications

          11

          FY, 2016

          Patents Licensed

          18

          FY, 2016

          LocationsView all

          1 location detected

          • Burlingame, CA HQ

            United States

            863 Mitten Rd #102

          Corvus Pharmaceuticals Financials

          Summary Financials

          Net income (Q1, 2024)
          ($5.7M)
          Cash (FY, 2023)
          $12.6M
          EBIT (Q1, 2024)
          ($6.3M)
          Enterprise value
          $126.6M

          Footer menu